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Introduction
Hepatocellular Carcinoma (HCC) is extremely lethal
and an overall median survival without treatment is 1.6
months.1  There are two main causes of death: deterioration
due to tumour growth, and hepatic failure.  Prognostic
factors include size and number of lesions, vascular
invasion, infiltrative behavior, capsular invasion and distant
metastasis.  The prognosis is closely related to liver function
reserves.  Ohnishi et al2 reported the natural history of HCC
without treatment and demonstrated median survival times
of 37 months for Child's A, 16 months for Child's B and 2
months for Child's C patients.
Okuda et al1 introduced a simple and practical
staging system for HCC.  Only four clinical signs are used
for the staging (a) more than 50% tumour size (b) ascites (c)
less than 3mg/dl of serum albumin and (d) more than 3
mg/dl of serum bilirubin.
Stage I - no above signs
Stage II - 1-2 clinical signs
Stage III - 3-4 clinical signs
The median   survival of 229 patients with no
specific treatment at Stages I, II and III were 8.3 months, 2.0
months and 0.7 months respectively.
Detection of Early HCC
Establishment of screening ultrasound (US) and
serum AFP of high risk groups such as hepatitis B or C
carriers and liver cirrhotic patients and recent advances in
medical imaging technology permit the early detection of
small HCCs. The sensitivities of various imaging modalities
for HCC of <3 cms is reported as:3,4
Ultrasound 46 - 84%
Helical CT 54 - 84%
Angiography 81%
CT arterioportography 88%
Iodized Oil CT 93%
MRI 90%
Intra-operative US 96%
Japanese recommendation for screening cirrhotic
patients is to perform alpha-fetoprotein every 2 months, US
every 3 months and CT or MRI every 6 months.5
Treatment of HCC 
Hepatic resection offers the best chance at cure for
patients with hepatocellular carcinoma, but only 10-30% of
such patients are eligible for resection.6 In addition, the
recurrence rate in the remnant liver after a hepatectomy is
markedly high, ranging from 36% - 66%.
The second best option would be hepatic
transplantation, which is reserved for selected patients with
cirrhotic liver disease who have tumour (diameter, <5 cm)
in the context of neoadjuvant protocols. The long term
survival is higher than resection7,8 but treatment is restricted
due to limited facilities, selection criteria and long wait for
donor livers.
Unresectable HCCs pose a challenge to both
oncologists and interventional radiologists.  The results of
systemic chemotherapy and radiotherapy have been
disappointing with no appreciable impact on survival rates.9
Although the direct application of intra-arterial
chemotherapy into the feeding artery of a tumour is
theoretically much more effective and produces less toxicity
than systemic intravenous chemotherapy, the benefit and
safety of this treatment has not been proved in clinical
trials.10,11
Hepatic artery embolization, in combination with
chemotherapy was developed in Japan in early 80s for
unresectable HCC.12 It is now fairly well established as
primary treatment for non-resectable HCC.13 The rationale
for transarterial chemo-embolization (TACE) is that these
tumours especially the well-encapsulated lesions are mainly
fed by the hepatic artery. By contrast the infiltrative tumours
also have a supply from the portal vein.  On the basis of
many clinical studies14 it has been speculated that when
iodized oil (Lipoidol Ultra-Fluid) is used to embolize HCC,
the oil enters the sinusoids, where it is retained. Oil particles
have been found in the portal vein following an arterial
injection.  The oil is mixed with the cytotoxic agent such as
Cisplatinum, Doxorubicin, Epirubicin or Mitomycin C to
form a covalent conjugate, which is then injected into the
feeding artery.  The conjugate remains in the tumour acting
from both arterial and portal side and the cytotoxic agent is
slowly released to exert the chemotherapeutic effect.
Lipoidol serves as both the targeting agent that carries the
cytotoxic agent to the tumour, since it is selectively
deposited in it and the embolizing agent that causes
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blockade of neovasculature of the tumour.  The daughter
tumours are also dealt with in the segment or lobe which is
injected.15
Gelfoam particles appear to be essential to maximize
the therapeutic effect of TACE.  They increase the retention
of iodized oil by blocking washout.  Takuyasu et al16 found
that complete necrosis occurred in 83% with triple therapy
(Lipoidol, adriamycin and gelfoam), but occurred in only
13% with oil and adriamycin.
Results of TACE
Several reports from the 1990's consistently show a 2-
3 fold increase in median survival after chemoembolization
compared to untreated controls17,18 (Table).  Survival varies
directly with tumour encapsulation, oil uptake and
retention, and inversely with tumour volume, infiltration
and underlying liver disease.  Post-operative recurrent
HCCs have also been treated by TACE.19 Iodized oil can
reach recurrent tumours even through the small collateral
vessels that often develop after repeated TACE and previous
surgery.  Although unresectable tumours have become
resectable after successful TACE20, pre-operative TACE for
resectable HCCs is controversial.
Choice of Chemo Agent
Doxorubicin Hydrochloride (Adriamycin [ADR])
has been the main anticancer agent used in TACE. The
standard dose is 20-30 mg/m2 (20-90 mg; mean 40 mg). The
dose would be adjusted according to the size and number of
tumours, embolized area and liver function. 
Table. Western Series of TACE for Hepatocellular Carcinoma.
Median Survival
Autho Year Therapy No. Months P
Prospective, randomized
Pelletier30 1990 Dox + Gel 21 4 NS
Supportive Care 21 6
French group31 1995 Cis + Lip + Gel 50 19 0.13
Supportive Care 46 8
Retrospective, matched historical
Controls
Vetter32 1991 Dox + Lip + Gel 30 12 <0.001
Supportive Care 30 3
Bronowicki33 1994 Dox.Cis, or Epi+Lip+Gel 127 18 <0.0001
Supportive Care 127 5
Stefanini 34 1995 Dox + Lip + Gel 69 21 <0.001
Supportive Care 64 3
Retrospective, nonmatched controls
Bronowicki 35 1996 Dox,Cis,or Epi+Lip+Gel 42 36 <0.0001
Supportive Care 33 11
Stuart 36 1996 Dox + Lip + Gel 137 14 <0.01
Supportive Care 81 2
Marcos-Alvarez37 1996 Dox + Lip + Gel 30 13 <0.05
Supportive Care 22 5
Ryder38 1996 Dox + Lip + Gel 67 9 NA
Non-Surgical Therapy 118 3
Rose18 1998 Dox + Lip + Gel 35 9 <0.0001
Supportive Care 31 3
Dox = doxirubicin; Cis = cisplatin; Epi = epirubicin; Lip = lipiodol; Gel = gelatin-foam particles or powder; NS = not statistically significant; NA = not
applicable.
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Epirubicin (EPI), analog to Adriamycin, has less
acute toxicity (nausea, vomiting), less myelosuppression on
an equivalent milligram basis and higher total allowed
cumulative dose before the onset of congestive heart
failure.21 To attain equivalent biological effect of ADR,
approximately 25% more EPI must be given, so that 25-40
mg/m2 is equivalent to 20-30 mg/m2 of ADR.
Cisplatinum (60 mg/m2) and Mitomycin C (0.2
mg/Kg) are effective alternatives. They can be used when a
patient shows clinical evidence of ADR cardiotoxicity or
when a synergestic effect is anticipated.
Complications
Overall complication rate of TACE is reported to be
4.4%22 and related to the use of chemoembolic agents or the
manipulation of a catheter or guide wire. The most common
complication is post embolization syndrome (nausea,
vomiting, abdominal pain, loss of appetite and daily
intermittent fevers - temperature below 39oC). This
syndrome can occur with any solid organ embolization.
With current medical care (hydration, antiemetics and pain
control) the symptoms are well tolerated and 50% of
patients can be discharged from the hospital the day
following chemoembolization. Extent and duration of fever
appears to be related to the degree of tumour necrosis and to
tumour size. These symptoms improve with time. 
Other complications are listed below23:
1. Puncture site hematoma 1.6%
2. Peripheral artery occlusion 0.4%
3. Catheter induced complications 0.4%
4. Contrast media reactions 4.0%
5. Renal failure 2.4%
6. Prolonged fever 0.4%
7. Liver abscess 0.4%
8. Mortality 2.0%
9. Liver infarction 0.17%
10. Acute hepatic failure 0.26%
11. Intrahepatic biloma formation 0.87%
12. Cholecystitis and gallbladder infarction 0.30%
13. Splenic infarction 0.08%
14. GI mucosal lesions 0.22%
15. Tumour rupture 0.04%
16. Variceal bleeding 0.13%
Toxicity
Mild to moderate elevation of AST or LDH are
frequently noted that peaks at 3-5 days after TACE but
hepatic function usually recovers within a few weeks.24
Recovery of hepatic function is delayed in patients with
markedly decreased hepatic reserve. There is no sustained
degradation of liver function in properly selected patients
who do not meet the well-established exclusion criteria for
TACE, even in the presence of cirrhosis .25 Because most of
the injected drug is retained in the liver, systemic toxicity is
minimized, with little bone marrow suppression. The
cumulative toxicity is far more limited than is experienced
with systemic chemotherapy.
Factors, which can minimize hepatotoxicity  are:
1. Child A and Child B cirrhosis
2. Patent portal vein
3. Hepatopetal flow in portal vein
4. Superselective catheterization of tumour feeders
5. Use of gelfoam pledgets (>500um) rather than gelfoam
powder
6. Dose calculated according to the size of tumour and 
liver function reserve
TACE for Treatment of Liver Metastasis
Colorectal Metastasis
Phase II studies of chemoembolization for
metastasic colorectal cancers have been reported by several
centers in US with promising results. At the Boston Center
for liver cancer, 40 paients were chemoembolized26 with
5FU, Mitomycin C, oil and gelfoam. Sixty three percent had
partial or minor morphological responses and 62% had a
50% drop in CEA level. Median survival from first
chemoembolization was 10 months. At the University of
Pennysylvania, 51 patients were chemoembolized.27
Morphological stabilization or regression occurred in 72%,
CEA stabilized or regressed in 90% and the median duration
of response was 12 months. The ACR Imaging Network is
currently funding a multicenter Phase III randomized trial
of systemic chemotherapy with or without
chemoembolization for colorectal metastasis to liver.
Ocular Melanoma
Patients with ocular melanoma frequently develop
rapidly progressive fatal hepatic metastasis, with median
survival of 2-6 months. The M. D. Anderson Cancer Center
reported on 30 patients treated by chemoembolization.28
There was one complete response and 46% of the patients
had a >50% morphological response. Median survival was
11 months.
Neuroendocrine Tumours
Embolization has an established role in the palliation
of these hypervascular tumours, typically producing
symptom-free intervals of 5-10 months in 90-100% of
patients.29 Other investigators have warned of an increased
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complication rate for chemoembolization of carcinoid
tumours.
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